This Entry
PermalinkURI
URI Label
Revisions
Add to List
Edit Entry
Export:
XML
Archives
- November 2017 (1)
- August 2017 (1)
- February 2017 (1)
- January 2017 (2)
- June 2016 (1)
- May 2016 (1)
- December 2015 (1)
- November 2015 (2)
- September 2015 (1)
- July 2015 (1)
- June 2015 (3)
- May 2015 (1)
- January 2015 (1)
- December 2014 (1)
- November 2014 (2)
- September 2014 (4)
- August 2014 (2)
- July 2014 (3)
- June 2014 (1)
- May 2014 (3)
- April 2014 (2)
- February 2014 (2)
- January 2014 (1)
- December 2013 (2)
- November 2013 (3)
- October 2013 (1)
- September 2013 (1)
- August 2013 (2)
- July 2013 (2)
- May 2013 (1)
- April 2013 (1)
- February 2013 (2)
- January 2013 (1)
- December 2012 (2)
- November 2012 (1)
- October 2012 (2)
- July 2012 (2)
- May 2012 (4)
- April 2012 (2)
- March 2012 (2)
- January 2012 (3)
Authors
Sections
- 3D7 IC50 Avery Lab (3)
- AstraZeneca (2)
- MetID (3)
- Potencies GSK (1)
- Potencies Guy (1)
- Syngene (8)
- UCSD (1)
- Biology (37)
- DMPK (2)
- Dundee (4)
- GSH-EE - Chapman Lab (2)
- GSK PRR Assay (1)
- Imperial DGFA (1)
- Kirk Lab (5)
- Metabolism (1)
Tools
Show/Hide QR CodeShow/Hide Keys
Posted on behalf of Paul Willis
One member of the triazolopyrazines (Series 4) (MMV639565) had previously been evaluated in vivo and shown rapid parasite clearance. Data shown here.
Another member of the series (MMV669844) has now been tested in a snapshot (one dose level of 4 x 50 mg/Kg) efficacy SCID study at Swiss TPH. The compound had excellent efficacy as shown in the attached report (>99.9% inhibition of parasitimia) showing this appears a general property of the series.
MMV669844_SCID.pdf
Attached Files
MMV669844 and MMV639565.cdx
MMV669844 and MMV639565.png
MMV669844_SCID.pdf